Abstract
Background: In the past few years, great of attention has been paid to the identification and characterization of selective and potent inhibitors of the first identified histone demethylase LSD1, which may erase mono- and di-methylated histone 3 lysine 4 and 9. As the aberrant overexpression of LSD1 is involved in various pathological processes, especially cancer, obtaining selective and potent LSD1 inhibitors has emerged as a crucial issue in medicinal chemistry research.
Method: Until now, several LSD1 inhibitor screening models have been established, including enzyme coupled assay, LC-MS based assay, and FRET based assay. Nevertheless, due to some special instrument requirement and additional costs of LC-MS and FRET, the enzyme coupled assay is the most widely applied method for LSD1 inhibitor screening. Result: We summarized and compared several reported in vitro LSD1 inhibitor screening models. Each of them has distinct advantages and disadvantages, and none of these methods is perfect. In order to exclude the false positive results, at least one additional method should be applied to screen LSD1 inhibitors.Keywords: LSD1, inhibitor, screening model, enzyme coupled assay, LC-MS, FRET.
Current Medicinal Chemistry
Title:An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors
Volume: 24 Issue: 23
Author(s): Yi-Chao Zheng, Jiao Chang, Ting Zhang , Feng-Zhi Suo , Xiao-Bing Chen, Ying Liu , Bing Zhao, Bin Yu*Hong-Min Liu*
Affiliation:
- School of Pharmaceutical Sciences, Zhengzhou University, P.O. Box: 450001, Zhengzhou,China
- School of Pharmaceutical Sciences, Zhengzhou University, P.O. Box: 450001, Zhengzhou,China
Keywords: LSD1, inhibitor, screening model, enzyme coupled assay, LC-MS, FRET.
Abstract: Background: In the past few years, great of attention has been paid to the identification and characterization of selective and potent inhibitors of the first identified histone demethylase LSD1, which may erase mono- and di-methylated histone 3 lysine 4 and 9. As the aberrant overexpression of LSD1 is involved in various pathological processes, especially cancer, obtaining selective and potent LSD1 inhibitors has emerged as a crucial issue in medicinal chemistry research.
Method: Until now, several LSD1 inhibitor screening models have been established, including enzyme coupled assay, LC-MS based assay, and FRET based assay. Nevertheless, due to some special instrument requirement and additional costs of LC-MS and FRET, the enzyme coupled assay is the most widely applied method for LSD1 inhibitor screening. Result: We summarized and compared several reported in vitro LSD1 inhibitor screening models. Each of them has distinct advantages and disadvantages, and none of these methods is perfect. In order to exclude the false positive results, at least one additional method should be applied to screen LSD1 inhibitors.Export Options
About this article
Cite this article as:
Zheng Yi-Chao , Chang Jiao , Zhang Ting, Suo Feng-Zhi , Chen Xiao-Bing , Liu Ying , Zhao Bing , Yu Bin *, Liu Hong-Min*, An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors, Current Medicinal Chemistry 2017; 24 (23) . https://dx.doi.org/10.2174/0929867324666170509114321
DOI https://dx.doi.org/10.2174/0929867324666170509114321 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry Biological Activities of Eco-Friendly Synthesized Hantzsch Adducts
Medicinal Chemistry Overview of Medicinally Important Diterpenoids Derived from Plastids
Mini-Reviews in Medicinal Chemistry Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs
Current Pharmaceutical Biotechnology HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Natural Product Origins of Hsp90 Inhibitors
Current Cancer Drug Targets Dual Drug Conjugate Loaded Nanoparticles for the Treatment of Cancer
Current Drug Delivery Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer
Current Pharmaceutical Design FDG PET/CT in the Staging of Lung Cancer
Current Radiopharmaceuticals The Anti-Cancer Activity of Noscapine: A Review
Recent Patents on Anti-Cancer Drug Discovery RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors
Current Cancer Drug Targets Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents Adenoviral Vectors for Cancer Gene Therapy
Current Genomics A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer
Current Drug Targets ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Current Medicinal Chemistry Three Amino Acid Derivatives of Valproic Acid: Design, Synthesis, Theoretical and Experimental Evaluation as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Novel Kinase Inhibitors in Cancer Therapy (Guest Editors: Ezra E.W. Cohen and Nikolai G. Rainov)]
Reviews on Recent Clinical Trials